Takeda’s Inflammatory Bowel Drug’s Risks Questioned

Takeda Pharmaceutical Co.’s drug vedolizumab faces U.S. concern that its potential risk for a deadly brain infection outweighs the benefits in treating the two most common inflammatory bowel diseases.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.